Company intelligence / Profile preview

AmberGen

Watertown, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

AmberGen's Miralys spatial biology imaging reagents and MaxOmic Laboratory services are commercially available and actively used by top pharma and leading academic research organizations to image protein biomarkers and other molecules in tissue samples for disease research. These tools enable multiplexed, multimodal spatial imaging and analysis of fresh frozen and FFPE tissue samples, particularly aiding research in oncology, neurodegeneration, infectious, and chronic diseases. No clinical drug development programs.

Therapeutic areas: Infectious DiseasesOncologyNeurology
Modalities: ReagentAntibodyAntibody-drug conjugate
Industry: Pathology

Partnerships

Bruker Corporation

Beyond the preview

Go deeper on AmberGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AmberGen.

Explore the full profile